

Oncology Clinical Pathways

Salivary Gland Cancer

April 2022 – V1.2022



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Table of Contents

[Salivary Gland T1-2, N0, M0](#).....3


[Salivary Gland T3-4a, N0](#).....4

[Salivary Gland T1-4 Node Positive](#).....5

[Salivary Gland T4b](#).....6

[Salivary Gland Recurrent or Metastatic Disease](#).....7

Salivary Gland Cancer – T1-2, N0, M0



Clinical trial(s) always considered on pathway.

^a **Adverse Features** include positive margins, neural invasion, lymphovascular invasion

^b **Resection** surgical operations may be staged if needed dependent on pathology of primary tumor

^c **High or Intermediate Grade** includes adenoid cystic

^d **Surveillance** consider resection if low morbidity

^e **Adenoid Cystic** consider long-term surveillance > 5 years



Choose **VA**




SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Salivary Gland Cancer – T3-4a, N0




Clinical trial(s) always considered on pathway.

^a **Resection** surgical operations may be staged if needed dependent on pathology of primary tumor


^b **Neck Dissection** consider avoiding if subsequent radiation to the primary site includes a large measure of the nodal basin; radiation fields would need to be increased to provide therapeutic coverage of the neck

^c **Adverse Features include** intermediate or high grade, positive margins, neural invasion, multiple lymph nodes, advanced T stage (T3-4), extranodal extension, adenoid cystic, or lymphovascular invasion

Salivary Gland Cancer – T1-4 Node Positive




Salivary Gland Cancer – T4b



Clinical trial(s) always considered on pathway.

^a **Adverse Features include** intermediate or high grade, positive margins, neural invasion, multiple lymph nodes, advanced T stage (T3-4), extranodal extension, adenoid cystic, or lymphovascular invasion

Salivary Gland Cancer – Recurrent or Metastatic Disease



Clinical trial(s) always considered on pathway.

^a **Molecular Testing** to include HER2, NTRK gene fusion, TMB, and Androgen Receptor

^b **HER2** includes IHC, considered positive if 3+; if 2+ perform FISH testing

^c **Evidence base** is limited; limited data from phase 2 clinical trials; abiraterone is an acceptable alternative

^d **Leuprolide** prescribe for both men and women; in women, either pre or post menopause

^e **Cisplatin, doxorubicin, and cyclophosphamide** evaluate cardiovascular risk factors with baseline LVEF



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Questions?

Contact VHAOncologyPathways@va.gov



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs